Behind The Blockbuster: Investors Sound Off On Biogen's Future With Spinraza
Entering 2017 with freshly approved Spinraza and new CEO Michel Vounatsos, Biogen still faces challenges and uncertainty. A poll of investors highlights expectations for the company.
You may also be interested in...
Analysts expect strong uptake for the antisense oligonucleotide (ASO) given the high unmet need in SMA and positive data in multiple studies, while the first ASO approved this year – Sarepta’s Exondys 51 – has seen some pushback from payers despite the lack of DMD therapies.
In this installment of VC Playbook, profiling venture capital strategies in biopharma and medtech, In Vivo talks to Sofinnova’s Graziano Seghezzi about market access trends, Italy’s growing biotech offering and the perils of “health nationalism” to business partnering in the aftermath of COVID-19.
In this latest edition of the Lab Links series on notable figures responsible for major advances in drug discovery, In Vivo talks to Harvard Medical School professor and biologist Timothy Springer on his 50-year record as an academic scientist, business entrepreneur and philanthropist. His latest venture is being co-founder – and principal funder – of the independent non-profit Institute for Protein Innovation, an institution designed to fill a critical niche in open-source biomedical research.